Home > Riviste > Minerva Urology and Nephrology > Fascicoli precedenti > Minerva Urology and Nephrology 2021 August;73(4) > Minerva Urology and Nephrology 2021 August;73(4):442-51



Opzioni di pubblicazione
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca


Publication history
Per citare questo articolo


REVIEW   Free accessfree

Minerva Urology and Nephrology 2021 August;73(4):442-51

DOI: 10.23736/S2724-6051.21.04098-4


lingua: Inglese

The emerging landscape of tumor marker panels for the identification of aggressive prostate cancer: the perspective through bibliometric analysis of an Italian translational working group in uro-oncology

Matteo FERRO 1, Giuseppe LUCARELLI 2, Ottavio de COBELLI 1, 3, Francesco DEL GIUDICE 4, Gennaro MUSI 1, Francesco A. MISTRETTA 1, Stefano LUZZAGO 1, Gian M. BUSETTO 4, Carlo BUONERBA 5, Alessandro SCIARRA 4, Simon CONTI 6, Angelo PORRECA 7, Michele BATTAGLIA 2, Pasquale DITONNO 2, Matteo MANFREDI 8, Cristian FIORI 8, Francesco PORPIGLIA 8, Daniela TERRACCIANO 9

1 Department of Urology, IRCCS European Institute of Oncology (IEO), Milan, Italy; 2 Unit of Urology, Andrology and Kidney Transplantation, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy; 3 Department of Oncology and Hematology-Oncology, University of Milan, Milan, Italy; 4 Department of Urology, Sapienza University, Rome, Italy; 5 Service of Medical Oncology, Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy; 6 Department of Urology, Stanford University School of Medicine, Stanford, CA, USA; 7 Department of Urology, Abano Terme Hospital, Padua, Italy; 8 Division of Urology, Department of Oncology, School of Medicine, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy; 9 Department of Translational Medical Sciences, Federico II University, Naples, Italy

Molecular heterogeneity and availability of different therapeutic strategies are relevant clinical features of prostate cancer. On this basis, there is an urgent need to identify prognostic and predictive biomarkers for an individualized therapeutic approach. In this context, researchers focused their attention on biomarkers able to discriminate potential life-threatening from organ-confined disease. Such biomarker could provide aid in clinical decision making, helping to choose the treatment which ensures the best results in terms of patient survival and quality of life. To address this need, many new laboratory tests have been proposed, with a clear tendency to use panels of combined biomarkers. In this review we evaluate current data on the application in clinical practice of the most promising laboratory tests: Phi, 4K score and Stockholm 3 as circulating biomarkers, Mi-prostate score, Exo DX Prostate and Select MD-X as urinary biomarkers, Confirm MDx, Oncotype Dx, Prolaris and Decipher as tissue biomarkers. In particular, the ability of these tests in the identification of clinically significant PCa and their potential use for precision medicine have been explored in this review.

KEY WORDS: Prostatic neoplasms; Tumor biomarkers; Diagnosis

inizio pagina